Welcome!
To use the personalized features of this site, please log in or register.
If you have forgotten your username or password, we can help.
My Menu
Saved Items

Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease

L. Frölich1, D. Blum-Degen2, H.-G. Bernstein3, S. Engelsberger2, J. Humrich2, S. Laufer2, D. Muschner2, A. Thalheimer2, A. Türk2, S. Hoyer4, R. Zöchling5, K. W. Boissl5, K. Jellinger6 and P. Riederer2

(1)  Department of Psychiatry I, University of Frankfurt/Main,,
(2)  Department of Psychiatry, University of Würzburg,,
(3)  Department of Psychiatry, University of Magdeburg,,
(4)  Department of Pathochemistry and General Neurochemistry, University of Heidelberg, Federal Republic of Germany, DE
(5)  NÖ Landesnervenklinik, Mauer/Amstetten, and,
(6)  L. Boltzmann Institute of Clinical Neurobiology, Vienna, Austria, AT
Summary.   The search for the causes of neurodegenerative disorders is a major theme in brain research. Acquired disturbances of several aspects of cellular metabolism appear pathologically important in sporadic Alzheimer's disease (SDAT). Among these brain glucose utilisation is reduced in the early stages of the disease and the regulatory enzymes important for glucose metabolism are reduced. In the brain, insulin, insulin-like growth factors and their receptors regulate glucose metabolism and promote neuronal growth. To detect changes in the functional activity of the brain insulin neuromodulatory system of SDAT patients, we determined the concentrations of insulin and c-peptide as well as insulin receptor binding and IGF-I receptor binding in several regions of postmortem brain cortex during aging and Alzheimer's disease. Additionally, we performed immunohistochemical staining with antibodies against insulin in neocortical brain areas in SDAT and controls. We show for the first time that insulin and c-peptide concentration in the brain are correlated and decrease with aging, as do brain insulin receptor densities. Weak insulin-immunoreactivity could be demonstrated histochemically in pyramidal neurons of controls, whereas in SDAT a stronger insulin-immunoreactivity was found. On a biochemical level, insulin and c-peptide levels were reduced compared to middle-aged controls, but were unchanged compared to age-matched controls. Brain insulin receptor densities in SDAT were decreased compared to middle-aged controls, but increased in comparison to age-matched controls. IGF-I receptor densities were unchanged in aging and in SDAT. Tyrosine kinase activity, a signal transduction mechanism common to both receptor systems, was reduced in SDAT in comparison to middle-aged and age-matched control groups. These data are consistent with a neurotrophic role of insulin in the human brain and a disturbance of insulin signal transduction in SDAT brain and favor the hypothesis that insulin dependent functions may be of pathogenetic relevance in sporadic SDAT.

Keywords: Insulin - insulin receptor - Alzheimer's disease - aging.

Accepted November 11, 1997; received August 4, 1997

Fulltext Preview (Small, Large)
Image of the first page of the fulltext


Export this article
Export this article as RIS | Text
 
Referenced by
14 newer articles

  1. Rajala, Raju V. S. (2009) Insulin receptor signaling regulates actin cytoskeletal organization in developing photoreceptors. Journal of Neurochemistry
    [CrossRef]
  2. Isik, Ahmet Turan (2009) Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease. International Psychogeriatrics
    [CrossRef]
  3. Baquer, Najma Z. (2009) A metabolic and functional overview of brain aging linked to neurological disorders. Biogerontology
    [CrossRef]
  4. Chen, Y. (2009) Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proceedings of the National Academy of Sciences 106(10)
    [CrossRef]
  5. McIntyre, Roger S (2006) Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opinion on Pharmacotherapy 7(10)
    [CrossRef]
  6. Jolivalt, C.G. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase‐3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. Journal of Neuroscience Research
    [CrossRef]
  7. Pasinetti, Giulio Maria (2008) Metabolic syndrome and the role of dietary lifestyles in Alzheimer’s disease. Journal of Neurochemistry 0(0)
    [CrossRef]
  8. Watson, G. Stennis (2007) Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment. Progress in Neurotherapeutics and Neuropsychopharmacology
    [CrossRef]
  9. Torres-Aleman, Ignacio (2007) Targeting insulin-like growth factor-1 to treat Alzheimer's disease. Expert Opinion on Therapeutic Targets 11(12)
    [CrossRef]
  10. Whitmer, Rachel A. (2007) Type 2 diabetes and risk of cognitive impairment and dementia. Current Neurology and Neuroscience Reports 7(5)
    [CrossRef]
First | Next | Last
Remote Address: 38.107.191.82 • Server: mpweb20
HTTP User Agent: CCBot/1.0 (+http://www.commoncrawl.org/bot.html)